Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Pharma bankruptcy

    - PMLiVE

    Dendreon appoints new R&D lead

    Dr Bruce Brown joins the Californian biopharmaceutical group as senior VP

    - PMLiVE

    Valeant uncouples Dendreon and skincare brands to cut debt

    Agrees deals worth $2.1bn with L’Oreal and Sanpower Group

    NewLink

    NewLink pancreatic cancer vaccine flunks phase III test

    Survival rate slightly lower for patients on vaccine than those in control group

    - PMLiVE

    Dendreon wins IQWiG U-turn for its immunotherapy Provenge

    New data for its troubled cancer drug convinces German HTA body of its added benefit

    National Institute for Health and Care Excellence NICE logo

    Good NICE news for Pfizer, but Dendreon drug rejected

    Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

    - PMLiVE

    Valeant and Shire said to be evaluating potential Salix bids

    Valeant currently in final stages of Provenge acquisition

    - PMLiVE

    Valeant lead bidder for troubled Dendreon

    Willing to pay $296m for company behind prostate cancer vaccine Provenge

    - PMLiVE

    NICE says cost of Dendreon’s cancer vaccine is too high

    Another blow as the bankrupt company goes to auction next month

    - PMLiVE

    Dendreon to go to auction without initial bidder

    A selection for a bidder wanting to pay the minimum price has not been made

    - PMLiVE

    Dendreon files for bankruptcy protection

    Follows poor sales of cancer vaccine Provenge

    - PMLiVE

    Dendreon’s cancer vaccine wins EU approval

    Provenge approved for use in prostate cancer three years after US recommendation

    - PMLiVE

    Lindsay Rocco to lead corporate communications at Dendreon

    Joins from agency Rx Mosaic Health

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links